Identification of a Goblet Cell-specific Enhancer Element in the Rat Intestinal Trefoil Factor Gene Promoter Bound by a Goblet Cell Nuclear Protein*

Haruhiko Ogata, Nagamu Inoue, and Daniel K. PodolskyDagger

From the Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Intestinal trefoil factor (ITF) is selectively expressed in goblet cells of the small and large intestinal mucosa. Detailed analysis of the rat ITF (RITF) promoter was undertaken by transient transfection and gel mobility shift assays (GMSAs) using the goblet cell-like LS174T colon cancer-derived cell line. Various lengths of wild-type or mutant constructs of the 5'-flanking region were linked to the pXP2 reporter gene luciferase. Expression of -118 RITF was significantly decreased compared with -154 RITF, and transfection with an 18-base pair construct (-141 to -124) resulted in more than 5-fold greater expression than transfection with the promoterless pXP2 gene construct alone. Using various synthetic oligonucleotide mutants, GMSAs revealed that only a 9-base pair sequence (CCCCTCCCC) in this element was required for specific binding, overlapping but distinct from a Sp1-like element. GMSA demonstrated that this element was specifically bound by nuclear proteins from intestinal cells with a goblet cell-like phenotype. These studies demonstrate that a 9-base pair element (goblet cell response element) between -154 and -118 in the RITF promoter gene is a cis-active element bound by a distinct nuclear transcription factor and is capable of directing intestine and goblet cell-specific expression.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Trefoil factors are a family of small peptides expressed at various sites throughout the gastrointestinal tract. The members of this family share an array of structural features including a distinctive motif of six cysteine residues termed a trefoil or a P domain. Thim (1) postulated that the six cysteine residues could contribute to the formation of three intrachain loops via the formation of disulfide bonds; the resultant predicted three-looped structure prompted the trefoil designation. A recent nuclear magnetic resonance analysis as well as x-ray crystallography of one of the trefoil peptides supported the presence of a distinctive secondary structure consistent with the putative three-intrachain loop formation (2). Members of the family identified in mammals possess one or two P domains (3-5). Amphibians have been found to express trefoil proteins with as many as four P domains (6).

Members of the trefoil peptide family appear to be expressed in a region-specific fashion along the length of the gastrointestinal tract. Human spasmolytic polypeptide bears two trefoil motifs and is expressed primarily in the stomach (5), although the porcine homologue was originally isolated from pancreas (7). pS2, bearing a single trefoil motif and initially cloned as the product of an estrogen-responsive gene from a breast cancer cell line (8), is normally expressed only in the gastric antrum in man (9). Cloning of the rodent homologues of pS2 and spasmolytic polypeptide confirmed that expression is site-specific along the longitudinal axis of the upper gastrointestinal tract in a pattern that has been conserved in evolution (10, 11).

Intestinal trefoil factor (ITF)1 is a third member of the trefoil peptide family identified in humans (12, 13), rats (14, 15), and mice (16, 17) that contains a single P domain. In contrast to pS2 and human spasmolytic polypeptide, ITF is normally selectively expressed in the normal small and large intestinal mucosa, complementing the pattern of expression of the other members of the family in the normal gastrointestinal tract. More specifically, ITF expression is normally confined to the goblet cell population within the intestinal epithelium (14).

Goblet cells of the small and large intestine secrete a complex mixture of mucin glycoprotein onto the cell surface, but their functional importance in gastrointestinal tract mucosa has not been well defined. Moreover the basis of selected gene expression responsible for the distinctive goblet cell phenotype has not been defined. Genes encoding the apomucin peptide backbones of mucin glycoproteins are enormous in size and highly complex, hampering progress in efforts to define the regulatory effect conferring goblet cell-specific expression. The selective expression of ITF in intestinal goblet cells suggests that characterization of the gene encoding this peptide may provide insight into regulatory elements responsible for goblet cell-specific gene expression. Among the trefoil family members, only the promoter of pS2 gene normally expressed in gastric mucosa has been partially characterized (18, 19). Although several genes expressed in the intestinal epithelium including fatty acid-binding protein (20), sucrase-isomaltase (21), and lactase (22) have been cloned and their regulatory elements studied, none are products of goblet cells.

Our previous report showed relatively high levels of specific expression in transient transfection studies using promoters as short as 154 bp of the 5'-flanking region of the rat ITF (RITF) gene. The presence of goblet cell-specific promoter element(s) within close proximity to the transcriptional start site was suggested by those preliminary efforts (15). Further investigation of the RITF promoter was undertaken, and a cis-active element capable of directing goblet cell-specific expression was identified within this region. Moreover, this element appears to be bound by a distinct nuclear transcription factor.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Plasmid DNA Constructs-- The promoterless luciferase gene construct pXP2 (23) was a gift from Dr. Lee Kaplan. The 5'-flanking region of the RITF gene, the 1671-bp fragment, was subcloned from pRITF20C containing the entire RITF gene into pXP2 vector to form the construct -1671 RITF-luc (1.7WT-luc) and transformed into competent E. coli DH5alpha 1 cells (CLONTECH Laboratories; Palo Alto, CA) as described previously (15). To confirm correct orientation and preservation of the start codon of luciferase, plasmid DNA was subjected to restriction mapping and sequencing of the insertion junctions.

Deletion constructs of the 5'-flanking region of the RITF gene driving the luciferase gene, -979 RITF-luc (1.0WT-luc) were derived from the -1671 RITF-luc construct, taking advantage of convenient restriction sites as described previously (15). Further deletion plasmids, -664 RITF-luc (0.7WT-luc), -336 RITF-luc (0.3WT-luc), -154 RITF-luc (0.2WT-luc), and -117 RITF-luc (0.1WT-luc), were constructed by treatment of -1671 RITF-Luc with exonuclease III and mung bean nuclease after creation of a 5'-overhang using BamHI digestion to cut the plasmid at the 5'-end of the promoter insert using commercially available reagents (Erase-a-Base System, Promega, Madison, WI). -77 RITF-luc (0.08WT-luc) and -46 RITF-luc (0.05WT-luc) were generated by ligation of KpnI- and BglII-digested polymerase chain reaction product derived from the 1.7WT-luc into the restriction site of the pXP2 vector. Minimal promoter DNA constructs containing wild-type (WT) or mutant elements (M) spanning -154 to -118 (WT1-luc) and -141 to -124 (WT2-luc or M3- to M8-luc) were generated by ligation of kinased double-stranded synthetic oligonucleotides into the BamHI site of the pXP2 vector.

The other deletions and mutants using full-length RITF promoter (1.7WT-luc) were prepared by replacing the wild-type sequence with deleted or mutated sequences generated by Transformer site-directed mutagenesis kit (CLONTECH). 1.7Delta 1-luc represented deletion mutant with the deleted sequences from -154 to -118 and 1.7Delta 2-luc from -141 to -124. The nucleotides for mutagenesis were chosen from the sequence between -141 and -124, and those mutated constructs were designated as 1.7M3- to 1.7M8-luc.

All constructs were verified by DNA sequencing using the Sequenase version 2.0 DNA sequencing kit (Amersham Life Science, Inc.). Plasmid preparation purity was confirmed by A260/280 of > 1.6, and supercoiling of DNA was established by the appearance on agarose gel electrophoresis prior to use in transfection experiments.

Cell Cultures-- Human colon cancer cell lines LS174T and Caco-2, rat intestinal epithelial cell line IEC-6, human hepatocellular carcinoma cell line HepG2, and human cervix epithelioid cancer cell line HeLa obtained from the American Type Culture Collection (ATCC, Rockville, MD) were grown in Eagle's minimum essential medium except IEC-6 in Dulbecco's modified Eagle's medium supplemented with 4.5 g/liter D-glucose, 10% fetal calf serum, Eagle's balanced salt solution, nonessential amino acids, sodium pyruvate, 4 mM L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin. The H2 subclone of human colon cancer cell line HT-29 originally obtained from Dr. Daniel Louvard was grown in either Dulbecco's modified Eagle's medium with glucose (undifferentiating conditions) or in the presence of galactose as the sole source of carbohydrate to induce goblet cell-like differentiation as described previously (24, 25). All cell lines were grown in 5% CO2 at 37 °C.

Transient Transfection Promoter Analysis-- Transient transfection was accomplished by the calcium phosphate precipitation method. Sixteen hours prior to transfection, 8 × 105 cells were plated out in triplicate in 35-mm wells of a six-well cell culture plate. Complete media was refreshed 2 h prior to transfection. Efficiency of transfection was standardized by co-precipitation of the construct of interest with pTK-GH, consisting of the minimal thymidine kinase promoter driving the human growth hormone gene as a reporter gene (26), and adjusting for the amount of human growth hormone expressed, as determined by a commercially available radioimmunoassay (hGH Allegro Kit, Nichols Institute Diagnostics, San Juan Capistrano, CA). Calcium phosphate-precipitated plasmid DNA was added to each well and incubated at constant 5% CO2 for 4 h before a 2-min exposure to 15% glycerol. Cells were subsequently cultured for 48 h prior to assay for reporter gene expression. For determination of luciferase activity, cells were lysed and assayed immediately using a commercial luciferase assay system (Promega) measured in a luminometer (Analytical Luminescence Laboratory, Monolite 2010). Luciferase activity was adjusted for transfection efficiency reflected in the level of growth hormone, expressed as nanograms of hGH/ml of medium. Where noted, promoter activity was expressed as a percentage of the expression of the maximal promoter construct RSV-luc (a gift from Dr. Loyal Tillotson), consisting of the RSV promoter joined to the luciferase gene, or a -fold increase of the expression of the pXP2.

Nuclear Extracts and Gel Mobility Shift Assays (GMSAs)-- Nuclear extracts from cultured intestinal cells were prepared by Nonidet P-40 detergent lysis and 0.5 M NaCl extraction as described by Schreiber et al. (27). Nuclear extracts from other cell lines for GMSA tissue distribution studies were a kind gift from Drs. Anil K. Rustgi and Timothy C. Wang. Protein concentration was determined according to the Bradford assay (28). The wild-type, double-stranded synthetic probes used in this study were -154TTTTCCTCCCTAACCCTCTCCCCTCCCCCTCGGACTC-118 (WT1) and -141CCCTCTCCCCTCCCCCTC-124 (WT2) and were labeled by Klenow fill-in reaction in a buffer consisting of 10 mM Tris-HCl; 5 mM MgCl2; 7.5 mM dithiothreitol; 33 µM concentration of dATP, dGTP, and dTTP; 0.33 µM [alpha -32P]dCTP; and 1 unit of DNA polymerase I Klenow fragment and then polyacrylamide gel-purified. The Sp1 oligonucleotide was used as a control probe and was labeled by the same reaction. GMSAs were carried out by incubating 10 µg of nuclear extract with 5 fmol of probe (20,000 cpm) in a 20-µl binding reaction containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM ZnCl2, 1 mM dithiothreitol, 1 mM EDTA, 10% glycerol, and 1 µg of poly(dA-dT). In experiments comparing binding by nuclear extracts between Sp1 and goblet cell-response element (GCRE) probes, 1 mM ZnCl2 was added to both reaction mixtures. After incubation at room temperature for 30 min, samples were loaded onto 6% polyacrylamide, 0.25 × Tris borate gels and electrophoresed at 10 V/cm for 2 h. Competition experiments were carried out by preincubating the nuclear extracts with a 100-fold excess of unlabeled wild-type (WT1 or WT2) or mutant (M1-8) competitor oligonucleotides prior to the addition of the probe. The consensus motif Sp1 (TAAGCTAGCCCCGCCCCGCTCG) oligonucleotide used as a competitor corresponds to the binding site found in the simian virus 40 early promoter (29). The antibodies against Sp1 (alpha Sp1) and Sp3 (alpha Sp3), purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), were incubated with nuclear extracts for 30 min at room temperature prior to GMSAs. The gels were dried and exposed to Kodak X-AR film for 6-24 h at -80 °C.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Expression of the Reporter Gene Luciferase under the Control of Deletions of Rat ITF 5'-Flanking Region in LS174T Cells-- Constructs in which various lengths of wild-type and mutant 5'-flanking region of the RITF gene were ligated to the reporter luciferase were transfected into LS174T cells, a goblet cell-like intestinal cell line. The level of expression of the various deletion constructs containing from -1671 to -154 of the 5'-flanking region (1.7WT-, 1.0WT-, 0.7WT-, 0.3WT-, and 0.2WT-luc) was between 8 and 11% of the expression observed for the maximal promoter-reporter construct, RSV-luc, in the LS174T cells. In contrast, the gene expression of the construct containing -117 of the 5'-flanking region (0.1WT-luc) was significantly decreased to 2% (Fig. 1). Decreased gene expression of the mutant construct deleted between -154 and -118 (1.7Delta 1-luc) was also observed compared with expression of wild-type full-length construct 1.7WT-luc. The level of expression in Caco2 cells, representing a columnar absorptive-like enterocyte phenotype, was consistently less than 2% that of RSV-luc, consistent with previous observations (15). These results suggest that element(s) between -154 and -118 of the RITF 5'-flanking sequences are able to enhance expression in a goblet cell-specific manner.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Transient expression of RITF promoter constructs in LS174T cells. Deletion constructs (1.7WT-, 1.0WT-, 0.7WT-, 0.3WT-, 0.2WT-, and 0.1WT-luc) are numbered according to the length of the 5'-flanking region relative to the transcriptional start site determined previously by RNase protection assay (15). 1.7Delta 1-luc is a site-directed mutagenesis construct deleted from -154 to -118. pXP2 is a promoterless luciferase construct. Plasmid constructs were transfected by the calcium phosphate precipitation method. Results are expressed as a percentage of luciferase activity compared with cells transfected with the maximal RSV promoter-driving luciferase gene. Luciferase activity was measured as relative light units adjusted for efficiency of transfection standardized by co-transfection of pTK-GH, the human growth hormone gene under the influence of the thymidine kinase promoter. The latter was assessed by determination of human growth hormone immunoreactivity in the media of the transfected well using a commercially available radioimmunoassay as described under "Materials and Methods." Results are the average of three independent transfections and are expressed as the mean ± S.E.

Characterization of Nuclear Protein from LS174T Cells Binding to GCRE in RITF Gene Promoter-- Two synthetic oligonucleotides of different length and corresponding mutants were generated as probes or competitors for use in GMSA experiments to assess nuclear extracts from the goblet cell line for the presence of proteins interacting with the 5'-flanking region implicated in transient transfection studies. Wild-type probe 1 (WT1) spanning -154 to -118 and wild-type probe 2 (WT2) spanning -141 to -124 were radiolabeled. Mutations of WT1 probe, both upstream (M1) and downstream (M2) of WT2 sequences, were also prepared (Fig. 2A). DNA-binding protein complexes derived from nuclear extracts of the LS174T cells appeared to be similar between the GMSA using WT1 and WT2 probe. Two major bands closely similar in size were present as demonstrated in Fig. 2B. Furthermore, competition studies from the GMSA using WT1 probe showed that the M1, M2, and WT2 oligonucleotides competed for binding to those proteins equally with the unlabeled WT1 probe. These data suggested that a DNA-binding site for the two proteins is present within the 18 bp (-141 to -124) corresponding to the WT2 probe. Therefore, subsequent GMSA experiments were undertaken with WT2 as a probe.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 2.   Binding of LS174T nuclear extracts to RITF promoter sequences probed with two oligonucleotides of different lengths by GMSA. A, DNA sequences of 37- and 18-bp elements of wild-type radiolabeled probe (WT1 and WT2) and mutant competitors (M1 and M2) spanned -154 to -118 (WT1, M1, and M2) and -141 to -124 (WT2) elements as indicated. B, radiolabeled probe WT1 or WT2 was mixed with nuclear extract prepared from LS174T cells in the absence or presence of a 100-fold excess of unlabeled, double-stranded DNA wild-type (WT1 and WT2) and mutant (M1 and M2) competitors as described under "Materials and Methods." Two major bands representing protein-DNA complexes and unbound probes are indicated by arrows.

To explore interactions between nuclear protein(s) from LS174T cells and the cis-regulatory element(s) between -141 and -124, GMSAs were carried out with mutant competitors throughout the 18-bp element. Nucleotide substitutions in mutants M3 to M8 are indicated in Fig. 3A. Competition experiments using a 100-fold molar excess of unlabeled WT2 probe revealed that the wild-type sequences compete for binding to the two major protein complexes. Similar competition resulted from use of the three mutants M3, M4, and M8. However, mutated sequences between -135 and -127, corresponding to M5, M6, and M7 mutant competitors, did not affect the binding reaction of those proteins with the probe (Fig. 3B). This analysis demonstrates that there were two proteins bound specifically to a 9-bp sequence in WT2 probe; the latter is accordingly designated the GCRE.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Identification of nuclear protein binding to GCRE by GMSA. A, DNA sequences of an 18-bp element of wild-type radiolabeled probe (WT2) and mutant competitors (M3-M8) spanning -141 to -124. The implicated GCRE binding site is marked by a rectangle. B, gel mobility shift assay of LS174T nuclear extracts probed with WT2 in the absence or presence of the unlabeled competitors. The binding reaction was performed as described in the legend to Fig. 2 and under "Materials and Methods." Two major bands representing protein-DNA complexes and unbound probes are indicated by arrows.

The 9-bp element initially identified as the GCRE appeared to be different from consensus sequences of previously described cis-elements with the possible exception of Sp1 (CCGCCC). The DNA binding specificity of the protein complexes was assessed in competition experiments using oligonucleotides representing consensus sequences for Sp1 and mutated Sp1 (mSp1) (Fig. 4A) and nuclear extract prepared from LS174T cells (Fig. 4B). DNA binding of protein was saturable because the excess of unlabeled WT2 probe in the binding reaction mixture blocked the formation of all DNA-protein complexes (Fig. 4B). The addition of Sp1-binding oligonucleotides to the binding mixture competed with formation of one protein complex (upper band), but not the other major complex formed between nuclear proteins and GCRE. The addition of mutated Sp1 did not affect either complex (Fig. 4B). Antibody against Sp1 could imperfectly abolish the upper band, and supershift by the antibody was not observed. Antibody against Sp3, another member of the Sp family did not affect either band. These findings suggest that the upper band may reflect the presence of a member of the Sp family (Sp1-like, not Sp3) that is able to bind to the Sp1 binding site. Taken together, the presence of a band in GMSA that is not affected by Sp1 competitors suggests that a 9-bp palindromic sequence (-135CCCCTCCCC-127) of GCRE that overlaps but is distinct from an Sp1-like element in the RITF gene promoter is specifically bound by a goblet nuclear factor.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 4.   Identification of Sp1-like protein specifically bound to RITF gene promoter element. A, unlabeled competitor oligonucleotides are represented as indicated: WT2, Sp1 consensus (Sp1), and Sp1 consensus binding site mutant (mSp1). The expected GCRE binding site is marked by a rectangle. The Sp1 and the Sp1-like binding sites are indicated by an underline and a dashed line, respectively. B, GMSA was performed with nuclear protein extracts prepared from LS174T cells and radiolabeled wild-type probe (WT2) after preincubation with a 100-fold molar excess of unlabeled competitor oligonucleotides. Antibodies specific for Sp1 (alpha Sp1) and Sp3 (alpha Sp3) were included as indicated.

Gene Expression Analysis of the Mutated RITF Gene Promoter-- To determine whether binding of GCRE in GMSA correlates with enhancer activity of this element, the effects of various mutations in -154 to -118 nucleotides of the RITF promoter gene expression were assessed by transient transfection assay. Minimal DNA constructs containing the wild-type 37-bp element (WT1, -154 to -118) or 18-bp element (WT2, -141 to -124) and the mutant 18-bp element (M3 to M8, -141 to -124) were generated using synthetic oligonucleotides subcloned into pXP2, and the resulting constructs were designated WT1-luc, WT2-luc, or M3- to M8-luc, respectively (Fig. 5A). Constructs were transiently transfected into LS174T cells, and gene expression was analyzed by measuring relative luciferase activity and represented as -fold increase of the activity of pXP2 (Fig. 5A). Transfections with WT1-luc and WT2-luc resulted in more than 5-fold greater (5.8-fold with WT1-luc and 5.2-fold with WT2-luc) expression than transfection with pXP2 alone. There was no significant difference in expression between WT1-luc and WT2-luc (Fig. 5A). Although mutations M3, M4, and M8 had no effect on wild-type WT2-luc expression, mutant constructs (M5-, M6-, and M7-luc) reduced expression nearly to the base line observed with the minimal construct pXP2 (Fig. 5A). The mutated sequences of M5 to M7 corresponded to the same 9-bp (-135 to -127) element of GCRE identified through GMSA (Fig. 4).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Transient expression of mutants of goblet cell-specific RITF gene enhancer element. LS174T cells were transiently transfected using the calcium phosphate precipitation method as described in the legend to Fig. 1 and under "Materials and Methods." A, minimal DNA constructs containing the wild-type (WT1 and WT2) or mutant (M3-M8) elements spanning -154 to -118 (WT1) or -141 to -124 (WT2 and M3-M8) RITF promoter were generated using synthetic oligonucleotides subcloned into pXP2 luciferase reporter gene. Relative luciferase activity was expressed as -fold increase of the expression of the pXP2. B, constructs 1.7 Delta 1-luc and 1.7 Delta 2-luc represent the deletion mutants with the deleted sequences indicated by broken lines. The nucleotides chosen for mutagenesis and the corresponding mutated nucleotides are the same as those shown in Fig. 5A. Results are expressed as a percentage of RSV promoter-driven luciferase activity. All results are the average of three independent transfections and are expressed as the mean ± S.E.

The role of the GCRE in the context of the full-length promoter was assessed through the preparation of full-length constructs containing mutations in the region -154 to -118 analogous to the mutants prepared in association with the minimal promoter. Constructs containing 3'-deletion mutants with the deleted sequences (1.7Delta 1-luc deleted -154 to -118, and 1.7Delta 2-luc deleted -141 to -124) and those (1.7M3- to 1.7M8-luc) mutated in the same positions as represented in M3- to M8-luc indicated in Fig. 5A were generated by site-directed mutagenesis assay as described under "Materials and Methods" (Fig. 5B). After transfection into LS174T cells, promoter activities were analyzed and expressed as a percentage of the expression of the maximal promoter construct RSV-luc (Fig. 5B). As expected, the expression of the deleted mutants (1.7Delta 1-luc and 1.7Delta 2-luc) and the expression of the mutants M5 to M7 were significantly decreased compared with the wild-type construct (1.7WT-luc) or constructs mutated at other sites within the 18-bp element (1.7M3-, 1.7M4-, and 1.7M8-luc) (Fig. 5B). These results were compatible with results from studies using the minimal DNA constructs and further implicate the GCRE as a key regulatory element promoting expression of RITF.

Characterization of Nuclear Proteins from Intestinal Epithelial Cell Lines Binding to GCRE-- Using nuclear extracts from various kinds of intestinal cell lines, GMSA was performed to characterize the protein complexes bound to GCRE. To ensure the quality of nuclear protein extracts, GMSA using a consensus Sp1 site as a probe was also performed (Fig. 6B). Crude nuclear protein extracts were prepared from LS174T (5 µg), HT29 (5 µg), undifferentiated (7.5 µg) or differentiated H2 (2.5 µg) subclone of HT29, and Caco2 (2.5 µg) cells, and binding reactions were carried out with the Sp1 or WT2 probe. As sufficient Zn2+ was chelated by the EDTA present in the nuclear extract isolation buffer to prevent Sp1 from binding (30), 1 mM ZnCl2 was added to the GMSA reactions. All of the nuclear proteins bound the Sp1 consensus sequence (Fig. 6A). The identity of the Sp1-binding protein was confirmed by supershift after the addition of anti-Sp1 antibody. These data demonstrated the presence of equal Sp1 binding activity, confirming the adequacy of nuclear extracts from the different cell lines. Using the same reaction conditions, the nuclear proteins from HT29 and Caco2 cells did not appear to bind the GCRE, but strong binding to GCRE was observed by nuclear proteins from LS174T and differentiated H2 cells (Fig. 6B). While little binding of GCRE was observed with nuclear proteins from undifferentiated H2 cells, binding to GCRE was significantly greater by nuclear proteins prepared from H2 cells after goblet cell-like differentiation. These results suggest that expression of nuclear factors that bind to GCRE is associated with differentiation to a goblet cell-like phenotype.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Characterization of Sp1 and GCRE binding by nuclear proteins from intestinal epithelial cell lines. Crude nuclear protein extracts were prepared from various colonic cancer cell lines as indicated: LS174T, HT29, H2 undifferentiated (H2-u), H2 differentiated (H2-d), and Caco2. A, the binding reaction was performed with nuclear protein extracts from each cell line and radiolabeled probe in the absence or presence of unlabeled WT2 competitor. The amounts of nuclear protein were adjusted so that the biding activity in each cell line showed the same strength (LS174T, 5 µg; HT29, 5 µg; H2 undifferentiated, 7.5 µg; H2 differentiated, 2.5 µg; and Caco2, 2.5 µg). a, Sp1; f, free probes. The supershifted complexes by the Sp1 antibody are indicated (s). B, using the same amounts of nuclear protein extracts indicated in A, the reaction was performed with radiolabeled WT2 probe in the absence or presence of unlabeled WT2 competitor. a, binding to WT2; f, free probe.

Characterization of Tissue Specificity of the GCRE and Its Binding Protein-- GMSA was carried out using nuclear extracts made from cell lines derived from a variety of tissues to further characterize the specificity of expression of the GCRE-binding proteins. As shown in Fig. 7, the GCRE-binding nuclear factor was largely absent in nongoblet cell lines with the exception of HepG2 (liver) and HeLa (cervix) cells. A very small amount of binding protein was also observed in lung (LX-1) cells. Of interest, little binding to GCRE was observed by nuclear proteins from IEC6 cells, a nontransformed rat intestinal crypt cell line. Binding to Sp1 was observed by all of the nuclear proteins in the same fashion as shown in Fig. 6A (data not shown).


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 7.   Cell specificity of the GCRE-binding protein. GMSA was performed with radiolabeled WT2 probe and crude nuclear extracts made from a variety of cell lines. In addition to LS174T cells, cell lines included the following: TE-1, human esophageal cancer; AGS-B, human gastric cancer; Panc1, human pancreatic cancer; HepG2, human hepatocellular cancer; LLC-PK1, porcine kidney proximal tubule; LX-1, human lung cancer; MCF-7, human mammary adenocarcinoma; HeLa, human cervical adenocarcinoma; and IEC6, rat intestinal crypt epithelial cell. The arrows indicate the position of the delayed complex containing the GCRE-binding protein.

To determine whether the GCRE-binding proteins present in extracts from HepG2 and HeLa cells were the same as that in the extract from goblet cells (Fig. 7), transient transfection analysis was undertaken using these cell lines (Fig. 8). The wild-type constructs (1.7WT-luc, 0.2WT-luc, and 0.1WT-luc) and the mutant construct (1.7Delta 1-luc) deleted between -154 and -118 were transfected into HepG2 and HeLa cells as well as LS174T cells. Promoter activities were analyzed and expressed as a percentage of the expression of the maximal promoter construct RSV-luc (% RSV-luc) as described under "Materials and Methods" (Fig. 8). Expression of both the truncated minimal promoter 0.1WT-luc and the mutant 1.7Delta 1-luc were significantly reduced in transfected colonic LS174T cells, compared with expression levels of both the wild-type constructs 1.7WT-luc and 0.2WT-Luc. In contrast, a requirement for the 37-bp sequence was not observed in HepG2 or HeLa cells. Since expression of the truncated minimal promoter 0.1WT-luc in HepG2 and HeLa cells was still high, transient transfection analysis of further truncated constructs (0.08WT-luc and 0.05WT-luc) in these cells was performed (Fig. 8B). Expression of both 0.08WT-luc and 0.05WT-luc was less than 1% of RSV-luc. 0.05WT-luc did not contain TATA box by DNA sequencing, and expression of this construct was not surprisingly the same as the pXP2, the promoterless construct. Transfection analysis using LX-1 cells was also performed, but the expression of all constructs used in this experiment was less than 1% of RSV-luc (data not shown). These results suggest that the protein(s) from HepG2 and Hela cells that bind the enhancer sequence containing GCRE are distinct from those present in LS174T cells.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 8.   Expression of RITF promoter constructs in nonintestinal cell lines. HepG2 and HeLa cells were transiently transfected using the calcium phosphate precipitation method as described under Fig. 1 and "Materials and Methods." A, the deletion constructs (1.7WT-, 0.2WT-, and 0.1WT-luc) and a deletion mutant (1.7Delta 1-luc) were the same as those shown in Fig. 5. B, further deletion constructs (0.08WT-luc and 0.05WT-luc) were generated by polymerase chain reaction from 1.7WT-luc. Results are expressed as a percentage of RSV promoter-driven luciferase activity. All results are the average of three independent transfections and are expressed as the mean ± S.E. Data from LS174T cells are represented in Fig. 1 and shown for comparison.

Collectively, these studies indicate that a 9-bp element (the GCRE) of -135 and -127 in the RITF promoter is a cis-active element directing goblet cell-specific expression. This element appears to be bound by a distinct nuclear transcription factor present in goblet-like cell lines.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Goblet cells are abundant constituents of the surface epithelium within the small and large intestine, but characterization of the molecular basis of goblet cell differentiation and function has been quite limited. Differentiation of epithelial cells in the gastrointestinal tract is a complex and dynamic process. In normal mucosa, not only is the tissue-specific phenotype maintained along the longitudinal axis from esophagus to large bowel, but vertical differentiation from crypt to villus is sustained as well. Moreover, differentiation into several region-specific subpopulations is observed within the epithelium along the length of the gastrointestinal tract. Among the growing list of cloned genes whose products are intestine-specific, ITF represents the first within the gastrointestinal tract exclusively expressed by goblet cells. Following earlier initial studies of molecular cloning of the RITF gene (15), in this paper we report the identification of a goblet cell-specific enhancer element in the RITF gene promoter bound by a goblet cell nuclear protein.

Trefoil proteins, including ITF, are secreted onto the mucosal surface and appear to function to preserve mucosal integrity, protecting the epithelium from injury by a variety of noxious agents (31-33). Furthermore, these factors facilitate rapid healing after injury by promoting restitution, the initial phase of epithelial migration that reestablishes surface continuity (7, 31). Mice rendered deficient in ITF through targeted gene deletion are exquisitely sensitive to injury by standard agents (e.g. dextran sodium sulfate) due to impaired restitution (34). An ulcer-associated cell lineage has been reported to appear adjacent to areas of gastrointestinal ulceration, with cells containing EGF-immunostaining material in the base of the newly budding cell lineage and trefoil protein-producing cells appearing more distally along the developing ductule (35).

There has been limited past characterization of the trefoil gene regulatory elements and as yet no delineation of the regulatory elements that are responsible for the regional selective expression of the different trefoil peptides. The presence of an EGF-responsive element in the 5'-flanking region of the pS2 gene (19) has led to speculation about the role of EGF in inducing expression of trefoil proteins in response to mucosal injury (36). However, scrutiny of the 5'-flanking region of the ITF gene demonstrated no significant homology to known EGF response elements (15).

Transient expression of deletion constructs containing various lengths of RITF gene 5'-flanking region ligated to a luciferase reporter gene indicate that an element present between -154 and -118 of RITF 5'-flanking sequences is able to enhance expression in a goblet cell-specific manner (Fig. 1). Subsequent mutational analysis indicates that this regulatory potential is conferred by a 9-bp element. Moreover, GMSA demonstrates the presence of two proteins that bind specifically to the same sequence (CCCCTCCCC, named GCRE) in nuclear extracts of goblet cells (Figs. 2 and 3). A search of this 5'-flanking region of the RITF gene reveals none of the known regulatory elements that have been demonstrated to play a role in intestine-specific expression. Thus, with the exception of some AT repeats, no areas of significant homology appear to exist within the full-length RITF promoter and the reported 5'-flanking regions of the genes from human intestinal alkaline phosphatase (37), human intestinal fatty acid-binding protein (20), porcine aminopeptidase N (38), human and mouse sucrase-isomaltase (21, 39), or human lactase-phlorizin hydrolase (22). However, there is an Sp1-like motif (CCTCCCC) in the GCRE, and one of the two specific binding proteins appears to be one of the Sp binding proteins, a family of zinc finger proteins (Fig. 4). The Sp1 motif is present in the enhancer regions of diverse genes (40, 41). While it appears that one of the proteins present in nuclear extract from goblet cell-like lines binds in an Sp1-like fashion, it is also apparent that these extracts contain a protein that is distinct from an Sp1 element that binds the GCRE.

The GMSA using nuclear extracts from various undifferentiated H2 cells grown in standard conditions contains little GCRE-binding protein (Fig. 6). In contrast, differentiated H2 cells, which exhibit a goblet cell-like phenotype, contain much greater nuclear protein bound to GCRE than undifferentiated H2 cells. No specific binding reaction to GCRE is observed with the nuclear proteins from Caco2 cells, which exhibit a columnar enterocyte phenotype (Fig. 6). Although the DNA-protein complexes observed in experiments using the nuclear proteins from LS174T and H2 cells are the same in size and although their binding appears to be specific as indicated by competition assays, it remains possible that these GCRE-binding proteins are different. At a minimum, these studies indicate that intestinal cells that have differentiated to goblet cell-like phenotype possess nuclear binding proteins that recognize the GCRE.

The analysis of cell specificity of the GCRE and its binding protein demonstrate that the latter is specifically associated with intestinal goblet-like cells. No GCRE was observed in the nuclear proteins from esophagus, stomach, pancreas, kidney, or breast. While the GCRE-binding proteins are present in liver and cervix cell lines, it appears that this reflects the Sp1-binding protein and another factor that is distinct from that in goblet-like cells because transient transfection assays suggest that the binding of the GCRE sequence in these cells does not promote ITF transcription. Interestingly, IEC6 cells, a nontransformed intestinal epithelial cell line established in this laboratory from neonatal rat intestinal crypt cells (42), do not possess the nuclear factors that bind to the GCRE. Previous studies have shown that IEC6 cells do not have detectable RITF mRNA by Northern blot analysis (14). These findings suggest that some unknown regulatory factor exists for vertical differentiation from crypt to villus in small and large intestine. Transient transfection experiments comparing LS174T cells and cells derived from other organs suggest that the GCRE of the RITF gene promoter is capable of directing intestine and goblet cell-specific expression.

In summary, we have identified a goblet cell-specific enhancer element in RITF gene promoter bound by a goblet cell nuclear protein. Further characterization of this enhancer element may provide insight into the molecular basis of the goblet cell phenotype. Future studies may also identify the genetic elements responsible for "ectopic" expression of ITF in pathologic conditions.

    ACKNOWLEDGEMENTS

We thank Drs. T. C. Wang and H. Nakagawa at Massachusetts General Hospital for helpful discussions.

    FOOTNOTES

* These studies were supported by National Institutes of Health Grants DK46906 and DK43351.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Gastrointestinal Unit, Massachusetts General Hospital, Fruit St., Boston, MA 02114. Fax: 617-724-2136; E-mail: Podolsky.Daniel{at}mgh.harvard.edu.

1 The abbreviations used are: ITF, intestinal trefoil factor; RITF, rat intestinal trefoil factor; GCRE, goblet cell-response element; GMSA, gel mobility shift assay; EGF, epidermal growth factor; bp, base pair(s); WT, wild type; RSV, Rous sarcoma virus.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Thim, L. (1988) Biochem. J. 253, 309
  2. Carr, M. D. (1992) Biochemistry 31, 1998-2004[Medline] [Order article via Infotrieve]
  3. Hoffmann, W., and Hauser, F. (1993) Trends Biochem. Sci. 18, 239-243[CrossRef][Medline] [Order article via Infotrieve]
  4. Thim, L. (1989) FEBS Lett. 250, 85-90[CrossRef][Medline] [Order article via Infotrieve]
  5. Tomasetto, C., Rio, M.-C., Gautier, C., Wolf, C., Hareuveni, M., Chambon, P., and Lathe, R. (1990) EMBO J. 9, 407-414[Abstract]
  6. Hauser, F., and Hoffmann, W. (1992) J. Biol. Chem. 267, 24620-24624[Abstract/Free Full Text]
  7. Jørgensen, K. H., Thim, L., and Jacobsen, H. E. (1982) Regul. Pept. 3, 207-219[CrossRef][Medline] [Order article via Infotrieve]
  8. Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., and Chambon, P. (1982) Nucleic Acids Res. 10, 7895-7903[Abstract]
  9. Rio, M. C., Bellocq, J. P., Daniel, J. Y., Tomasetto, C., Lathe, R., Chenard, M. P., Batzenschlager, A., Chambon, P. (1988) Science 241, 705-708[Medline] [Order article via Infotrieve]
  10. Lefebvre, O., Wolf, C., Kédinger, M., Chenard, M. P., Tomasetto, C., Chambon, P., Rio, M. C. (1993) J. Cell Biol. 122, 191-198[Abstract]
  11. Jeffrey, G. P., Oates, P. S., Wang, T. C., Babyatsky, M. W., Brand, S. J. (1994) Gastroenterology 106, 336-345[Medline] [Order article via Infotrieve]
  12. Podolsky, D. K., Lynch-Devaney, K., Stow, J. L., Oates, P., Murgue, B., DeBeaumont, M., Sands, B. E., Mahida, Y. R. (1993) J. Biol. Chem. 268, 6694-6702[Abstract/Free Full Text]
  13. Seib, T., Dooley, S., and Welter, C. (1995) Biochem. Biophys. Res. Commun. 214, 195-199[CrossRef][Medline] [Order article via Infotrieve]
  14. Suemori, S., Lynch-Devaney, K., and Podolsky, D. K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11017-11021[Abstract]
  15. Sands, B. E., Ogata, H., Lynch-Devaney, K., DeBeaumont, M., Ezzell, R. M., Podolsky, D. K. (1995) J. Biol. Chem. 270, 9353-9361[Abstract/Free Full Text]
  16. Mashimo, H., Podolsky, D. K., and Fishman, M. C. (1995) Biochem. Biophys. Res. Commun. 210, 31-37[CrossRef][Medline] [Order article via Infotrieve]
  17. Tomita, M., Itoh, H., Ishikawa, N., Higa, A., Ide, H., Murakumo, Y., Maruyama, H., Koga, Y., and Nawa, Y. (1995) Biochem. J. 311, 293-297[Medline] [Order article via Infotrieve]
  18. Jeltsch, J. M., Roberts, M., Schatz, C., Garnier, J. M., Brown, A. M. C., Chambon, P. (1987) Nucleic Acids Res. 15, 1401-1414[Abstract]
  19. Nunez, A. M., Berry, M., Imler, J. L., Chambon, P. (1989) EMBO J. 8, 823-829[Abstract]
  20. Sweetser, D. A., Birkenmeier, E. H., Klisak, I. J., Zollman, S., Sparkes, R. S., Mohandas, T., Lusis, A. J., Gordon, J. I. (1987) J. Biol. Chem. 262, 16060-16071[Abstract/Free Full Text]
  21. Chantret, I., Lacasa, M., Chevalier, G., Ruf, J., Islam, I., Mantei, N., Edwards, Y., Swallow, D., and Rousset, M. (1992) Biochem. J. 285, 915-923[Medline] [Order article via Infotrieve]
  22. Boll, W., Wagner, P., and Mantei, N. (1991) Am. J. Hum. Genet. 48, 889-902[Medline] [Order article via Infotrieve]
  23. Nordeen, S. K. (1988) Biotechniques 6, 454-457[Medline] [Order article via Infotrieve]
  24. Huet, C., Sahuquillo-Merino, C., Coudrier, E., and Louvard, D. (1987) J. Cell Biol. 105, 345-357[Abstract]
  25. Phillips, T. E., Huet, C., Bilbo, P. R., Podolsky, D. K., Louvard, D., Neutra, M. R. (1988) Gastroenterology 94, 1390-1403[Medline] [Order article via Infotrieve]
  26. Selden, R. F., Howie, K. B., Rowe, M. E., Goodman, H. M., Moore, D. D. (1986) Mol. Cell. Biol. 6, 3173-3179[Medline] [Order article via Infotrieve]
  27. Schreiber, E., Matthias, P., Muller, M. M., Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
  28. Bradford, M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  29. Dynan, W. S., and Tjian, R. (1983) Cell 32, 669-680[Medline] [Order article via Infotrieve]
  30. Merchant, J. L., Shiotani, A., Mortensen, E. R., Shumarker, D. K., Abraczinskas, D. R. (1995) J. Biol. Chem. 270, 6314-6319[Abstract/Free Full Text]
  31. Babyatsky, M., W., DeBeaumont, M., Thim, L., and Podolsky, D. K. (1996) Gastroenterology 110, 489-497[Medline] [Order article via Infotrieve]
  32. Kindon, H., Pothoulakis, C., Thim, L., Lynch-Devaney, K., and Podolsky, D. K. (1995) Gastroenterology 109, 516-523[Medline] [Order article via Infotrieve]
  33. Playford, R. J., Marchbank, T., Chinery, R., Evison, R., Pignatelli, M., Boulton, R. A., Thim, L., Hanby, A. M. (1995) Gastroenterology 108, 108-116[Medline] [Order article via Infotrieve]
  34. Mashimo, H., Wu, D.-C., Podolsky, D. K., Fisherman, M. C. (1996) Science 274, 262-265[Abstract/Free Full Text]
  35. Wright, N. A., Poulsom, R., Stamp, G. W. H., Hall, P. A., Jeffery, R. E., Longcroft, J. M., Rio, M. C., Tomasetto, C., Chambon, P. (1990) J. Pathol. 162, 279-284[Medline] [Order article via Infotrieve]
  36. Chinery, R., Poulsom, R., Rogers, L. A., Jeffery, R. E., Longcroft, J. M., Hanby, A. M., Wright, N. A. (1992) Biochem. J. 285, 5-8[Medline] [Order article via Infotrieve]
  37. Millan, J. L. (1987) Nucleic Acids Res. 15, 10599[Medline] [Order article via Infotrieve]
  38. Olsen, J., Sjostrom, H., and Noren, O. (1989) FEBS Lett. 251, 275-281[CrossRef][Medline] [Order article via Infotrieve]
  39. Traber, P. G., Wu, G. D., and Wang, W. (1992) Mol. Cell. Biol. 12, 3614-3627[Abstract]
  40. Kadonaga, J. T., Courey, A. J., Ladika, J., and Tjian, R. (1988) Science 242, 1566[Medline] [Order article via Infotrieve]
  41. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., Tjian, R. (1987) Cell 51, 1079-1090[Medline] [Order article via Infotrieve]
  42. Quaroni, A., Wands, J., Trelstad, T. L., Isselbacher, K. J. (1979) J. Cell Biol. 80, 245-265


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.